Compare IE & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IE | ZYME |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2022 | 2022 |
| Metric | IE | ZYME |
|---|---|---|
| Price | $11.51 | $24.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $18.17 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.7M | 617.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | $3,244,000.00 | ★ $105,965,000.00 |
| Revenue This Year | $44.79 | $183.10 |
| Revenue Next Year | $16.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 11.82 | ★ 38.87 |
| 52 Week Low | $7.72 | $11.86 |
| 52 Week High | $21.55 | $29.75 |
| Indicator | IE | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 42.91 |
| Support Level | $8.53 | $22.28 |
| Resistance Level | $15.70 | $27.81 |
| Average True Range (ATR) | 0.87 | 0.87 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 2.57 | 12.93 |
Ivanhoe Electric Inc is a United States-based d minerals exploration company with a focus on developing mines from mineral deposits principally located in the United States. The company has four business segments; Santa Cruz Project; critical metals; data processing services; and energy storage. It derives a majority of its revenue from Canada. The Santa Cruz Project and critical metals segments are focused on mineral project exploration and development. The data processing segment provides data analytics, geophysical modeling, and artificial intelligence services for the mineral, oil & gas, and water exploration industries. The energy storage segment develops, manufactures, and installs vanadium flow batteries for grid-scale energy storage.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.